Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337733 | 1.00 | USP2 (0.32) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL2452716 | 1.00 | USP2 (0.32) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL1026859 | 0.98 | USP2 (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL1027415 | 0.98 | USP2 (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL80022 | 0.95 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3951641 | 0.95 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL16834123 | 0.89 | — | — | |
| SCHEMBL3980312 | 0.86 | — | — | |
| SCHEMBL3980085 | 0.86 | — | — | |
| SCHEMBL3598480 | 0.84 | DPP4 (0.31) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | USP2 3800/4885ALDH1A1 337/4885LMNA 2244/4885 |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | ITK, BLK, LMTK2 | USP2 2328/4885ALDH1A1 1664/4885LMNA 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.